Bridgewater Associates’s Ingevity NGVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.55M Buy
20,799
+3,433
+20% +$247K 0.01% 768
2026
Q1
$1.24M Sell
17,366
-16,035
-48% -$1.1M 0.01% 756
2025
Q4
$1.98M Buy
33,401
+14,022
+72% +$761K 0.01% 770
2025
Q3
$1.07M Buy
+19,379
New +$1.01M ﹤0.01% 845
2024
Q3
Sell
-19,035
Closed -$832K 871
2024
Q2
$832K Buy
+19,035
New +$920K ﹤0.01% 694
2024
Q1
Sell
-68,998
Closed -$3.26M 764
2023
Q4
$3.26M Sell
68,998
-36,032
-34% -$1.5M 0.02% 438
2023
Q3
$5M Buy
+105,030
New +$5.73M 0.03% 366

Other funds holding NGVT

Bridgewater Associates's NGVT Position: Q2 2026 in Review

Bridgewater Associates increased its Ingevity (NGVT) stake by 20% in Q2 2026, buying an estimated $247K and bringing the position to 20,799 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #768.

Bridgewater Associates first reported a position in NGVT in Q3 2023 and has held it in 7 quarters since. The position peaked at $5M in Q3 2023. 315 funds tracked by Wall St. Rank hold NGVT as of Q2 2026.

  • Bridgewater Associates held 20,799 shares of Ingevity worth $1.55M as of Q2 2026.
  • Bridgewater Associates bought 3,433 Ingevity shares in Q2 2026, an estimated $247K.
  • Ingevity made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #768 holding.
  • Bridgewater Associates first reported a position in Ingevity in Q3 2023 and has held it in 7 quarters since.
  • Bridgewater Associates's Ingevity position peaked at $5M in Q3 2023.
  • 315 funds tracked by Wall St. Rank held Ingevity as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.